资源环境科技发展态势分析平台

This rapid expert consultation focuses on monoclonal antibody (mAbs) therapies authorized for use in patients infected with SARS-CoV-2. This consultation describes the approaches taken in different jurisdictions at the federal, state, and local/institutional levels to ensure an effective, equitable, and fair allocation of mAbs and points to challenges in reaching underserved patients.

The National Academies of Sciences, Engineering, and Medicine convened a standing committee of experts to help inform the Office of Science and Technology Policy on critical science and policy issues related to emerging infectious diseases and other public health threats. The standing committee includes members with expertise in emerging infectious diseases, public health, public health preparedness and response, biological sciences, clinical care and crisis standards of care, risk communication, and regulatory issues.